MS Immunosuppression Debate - Home

Join the debate! A free on-line multimedia educational activity


After many years in which few pharmacologic agents were available to treat multiple sclerosis (MS), a dizzying variety of new agents are now available or will soon become available to delay progression of this difficult disease. In general, these new agents suppress or modulate different aspects of the immune system than those affected by the more established disease-modifying therapies.

In this activity, which is conducted in a town-hall format, 2 experts debate the appropriate use of these new agents, while discussants who treat MS patients every day chip in with their lively opinions. You are invited to weigh in with your management strategies in this interactive forum.


Click “Play” for a preview of the debate 

Defining MS treatment failure: Symptoms . . . or MRI?

For progression: Immunosuppressants . . . or immunomodulators?

For initial MS therapy: Newer agents . . . or tried-and-true therapies?

Click Here to Register 

Weigh risks vs benefits of the established and emerging agents

This video presentation includes case discussions by active community clinicians and MS experts who consider how effectively the emerging vs established immunologically active agents slow disease progression and what the long-term risks of such agents may be.

A maximum of 1.25 contact hours may be earned for successful completion of this activity.

There is no charge for this activity.

This activity is supported by an independent educational grant from Biogen Idec and Elan Pharmaceuticals.

Initial release date: December 31, 2010
Expiration date: December 30, 2011


For further information or a DVD of the debate suitable for group presentations, please call 845-436-9857 or email


sponsored by Annenberg and The MSEA
sponsored by Annenberg and The MSEA